Johnson & Johnson sets high standards for health equity and social impact through local resource investment

Deborah Guion, Head of Health Equity at Johnson & Johnson Australia and New Zealand, delved into the company’s dynamic journey towards prioritising health equity and social impact.

In this interview with Health Industry Hub, Ms Guion who heads up the role for J&J MedTech and J&J Innovative Medicine (previously Janssen) locally, highlighted several key factors driving the outcomes of the recently released ANZ Impact Report.

Ms Guion stressed the importance of senior leadership commitment in driving health equity and social impact, saying “Last year, our two managing directors, Sue Martin and Urs Voegeli took time to travel to Arnhem Land with me, and they sat and listened to community talk about the challenges they face.”

Shedding light on the initiatives with the most profound outcomes, she delved into Johnson & Johnson’s strategy for involving employees in social impact projects, emphasising the significance of cultivating a culture of shared responsibility.

When confronted with the inevitable challenges of driving social and community impact, Ms Guion acknowledged the complexities involved but emphasised the importance of persistence and adaptability.

Looking towards the future, Ms Guion highlighted the emerging trends in health equity and social impact within the industry. She emphasised the increasing integration of data-driven approaches, as well as the growing emphasis on partnerships and collective action to address pressing societal challenges.

“It is a great opportunity for knowledge sharing across the sector because ultimately, the community work that each of us are doing is for the greater benefit of humanity,” she stated.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.